Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
An overview of the lymphoma landscape from BSH 2017
New applications for MRD measurement in myeloma: MRD 'over time'
Clinical management of venetoclax in multiple myeloma
What is the potential of daratumumab in combination therapy for myeloma?